Alan Ezekowitz bought $468K of Septerna (SEPN)
Executed Mar 5 2025, disclosed Mar 6 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Mar 6 2025), the stock returned -0.7% (delay-adjusted); from the execution session (Mar 5 2025), -11.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Alan Ezekowitz (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Septerna, Inc. (SEPN). Across 1 priced purchase filing, the average 21-session return was -11.5% from execution and -0.7% from disclosure (delay-adjusted; derived). The largest single filing was $468K of SEPN (79,190 sh across 2 lots, as filed), executed Mar 5 2025.
Healthcare · Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule produc…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→